Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dacarbazine + Endostar
- Development stage
- Phase 2
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
dacarbazine + Endostar is a combination therapy consisting of the recombinant human endostatin (Endostar) and the alkylating chemotherapy agent dacarbazine. Endostar, developed by Simcere Pharmaceutical, is a potent endogenous angiogenesis inhibitor that targets tumor vascularization by inhibiting endothelial cell proliferation, migration, and tube formation. Dacarbazine is a small molecule alkylating agent that has been a standard treatment for metastatic melanoma, working by causing DNA damage to inhibit tumor cell division. The combination was evaluated in a Phase II trial for untreated metastatic melanoma without c-kit or BRAF mutations, showing significant improvements in progression-free survival and overall survival compared to dacarbazine alone. While Endostar is approved in China for non-small cell lung cancer, its use in combination with dacarbazine for melanoma remains in clinical development.
- Other names
- recombinant human endostatin + dacarbazineEndostar + DTIC
02
Targets
DNAITGA5:ITGB1 (Integrin α5β1)αVβ3 (Integrin αVβ3)VEGFA (Vascular endothelial growth factor A)VEGFR2 (Vascular endothelial growth factor receptor 2)FGF2
Beyond the preview
Go deeper on dacarbazine + Endostar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dacarbazine + Endostar.